Efficacy of YKP3089 in Patients With Photosensitive Epilepsy
Status:
Completed
Trial end date:
2010-01-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to evaluate the ability of a single oral dose of YKP3089 to abolish
or clearly reduce the IPS-induced photo-paroxysmal EEG response in photosensitive epilepsy
patients, and to measure the onset and duration of the effect. Several cohorts will be used,
to sequentially investigate different doses.